Table 1 Participant demographics, clinical characteristics and stimulation settings
Participant ID | PD2 | PD3 | PD7 | PD9 | Dystonia |
|---|---|---|---|---|---|
Demography | |||||
Age | 58 | 66 | 40 | 48 | 65 |
Gender | M | M | M | M | M |
Diagnosis | PD | PD | PD | PD | Dystonia |
Dx | 11 | 13 | 9 | 13 | 30 |
DBS stimulation settings | |||||
Stim target | STN | GPi | STN | GPi | GPi |
Pulse width (us) | 60 | 60 | 60/90 | 90 | 60 |
Stim amp. (mA) | L: 2.4 R: 3.1 | L: 3.7 R: 2.8 | L: 1.7–3.4 R: 1.7–3.4 | L: 3–3.7 R: 3–3.7 | L: 4.5 R: 3.5 |
Stim freq. (Hz) | 130.2 | 178.6 | 130.2 | 150.6 | 130.2 |
Stim contact | L: C+2− R: C+1− | L: C+1− R: C+1− | L: C+2− R: C+2− | L: C+2− R: C+2− | L: C+1− R: C+2− |
Symptoms and clinical characteristics | |||||
Medication details | A-HCL 100 mg (3 times daily) C-Ldopa 25–100 mg IR (5 times daily) | C-Ldopa 25–100 mg CR (1–2 tabs at bedtime) and 25–100 mg IR (3 times daily) | C-Ldopa 25–100 mg (1 time daily) Rasagiline (Azilect) 1 mg (1 time daily) | Rytary 195 mg (3 times daily) | – |
UPDRS-III (OFF) | 49 | 66 | 41 | 39 | – |
UPDRS-III (ON) | 5 | 24 | 14 | 16 | – |
UPDRS 1.7 | No sleep symptoms | Slight sleep symptoms | Slight sleep symptoms | Mild sleep symptoms | – |
UPDRS 1.8 | No daytime sleepiness | Mild daytime sleepiness | Moderate daytime sleepiness | Mild daytime sleepiness | – |
Sleep diagnosis | No sleep conditions | Nocturia, RBD | Daytime sleepiness | OSA, Insomnia | Restless Leg Syndrome |
Neuropsych report (pre-op) | No reported sleep disorder or conditions | Mild sleep difficulties, with nocturia and RBD | Day time sleepiness (strongest 4–5 pm), usually sleeps late and sleeps very little overnight | Had long-term difficulties sleeping before PD.Occasionally couldn’t fall asleep at night. | Good sleep. No movements /dystonia at night. Restless Leg Syndrome at night. |
